JPWO2021207335A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021207335A5 JPWO2021207335A5 JP2022561040A JP2022561040A JPWO2021207335A5 JP WO2021207335 A5 JPWO2021207335 A5 JP WO2021207335A5 JP 2022561040 A JP2022561040 A JP 2022561040A JP 2022561040 A JP2022561040 A JP 2022561040A JP WO2021207335 A5 JPWO2021207335 A5 JP WO2021207335A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical combination
- menin
- combination according
- cyp3a4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100030550 Menin Human genes 0.000 claims 29
- 101710169972 Menin Proteins 0.000 claims 29
- 239000003112 inhibitor Substances 0.000 claims 29
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 27
- 238000000034 method Methods 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229960001589 posaconazole Drugs 0.000 claims 3
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 claims 2
- 229960002402 cobicistat Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 2
- 229960004884 fluconazole Drugs 0.000 claims 2
- 229960004130 itraconazole Drugs 0.000 claims 2
- 229960004125 ketoconazole Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims 2
- 229960004740 voriconazole Drugs 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229960000517 boceprevir Drugs 0.000 claims 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical group O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960000562 conivaptan Drugs 0.000 claims 1
- JGBBVDFNZSRLIF-UHFFFAOYSA-N conivaptan Chemical compound C12=CC=CC=C2C=2[N]C(C)=NC=2CCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 JGBBVDFNZSRLIF-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000015201 grapefruit juice Nutrition 0.000 claims 1
- 229960001936 indinavir Drugs 0.000 claims 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 1
- 238000011283 initial treatment period Methods 0.000 claims 1
- 229960004525 lopinavir Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004438 mibefradil Drugs 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 229960000884 nelfinavir Drugs 0.000 claims 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 1
- 229960001852 saquinavir Drugs 0.000 claims 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 1
- 229960002935 telaprevir Drugs 0.000 claims 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims 1
- 108010017101 telaprevir Proteins 0.000 claims 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims 1
- 229960003250 telithromycin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006574P | 2020-04-07 | 2020-04-07 | |
| US63/006,574 | 2020-04-07 | ||
| PCT/US2021/026141 WO2021207335A1 (en) | 2020-04-07 | 2021-04-07 | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522166A JP2023522166A (ja) | 2023-05-29 |
| JP2023522166A5 JP2023522166A5 (https=) | 2024-04-16 |
| JPWO2021207335A5 true JPWO2021207335A5 (https=) | 2024-04-16 |
Family
ID=78023861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561040A Pending JP2023522166A (ja) | 2020-04-07 | 2021-04-07 | メニン阻害剤とcyp3a4阻害剤との組合せ、およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12564590B2 (https=) |
| EP (1) | EP4132932A4 (https=) |
| JP (1) | JP2023522166A (https=) |
| KR (1) | KR20230007359A (https=) |
| CN (3) | CN120393026A (https=) |
| AU (1) | AU2021252552A1 (https=) |
| CA (1) | CA3178691A1 (https=) |
| IL (1) | IL297039A (https=) |
| MX (1) | MX2022012471A (https=) |
| WO (1) | WO2021207335A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805215A1 (en) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
| JP7554829B2 (ja) | 2019-12-19 | 2024-09-20 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換直鎖スピロ誘導体 |
| MX2022012471A (es) | 2020-04-07 | 2022-11-30 | Syndax Pharmaceuticals Inc | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. |
| TW202311262A (zh) | 2021-05-14 | 2023-03-16 | 美商錫達斯醫藥股份有限公司 | Menin-mll交互作用之抑制劑 |
| WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| JP2025516558A (ja) * | 2022-05-09 | 2025-05-30 | シンダックス ファーマシューティカルズ, インコーポレイテッド | 癌治療のためのメニン-mll阻害剤 |
| CN120456907A (zh) * | 2022-11-02 | 2025-08-08 | 库拉肿瘤学公司 | 急性白血病的治疗方法 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2025106862A1 (en) * | 2023-11-17 | 2025-05-22 | Kura Oncology, Inc. | Methods of treating kit positive cancers with a menin inhibitor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5820915A (en) | 1996-06-27 | 1998-10-13 | Bioavailability Systems, L.L.C. | Method for the preparation of a first-pass effective citrus-derived substance and product thereof |
| US6124477A (en) | 1996-06-27 | 2000-09-26 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5990154A (en) | 1997-05-30 | 1999-11-23 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds and citrus extract |
| US6063809A (en) | 1997-08-26 | 2000-05-16 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US6248776B1 (en) | 1997-08-26 | 2001-06-19 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| US5993887A (en) | 1998-06-29 | 1999-11-30 | Bioavailability Systems, L.L.C. | Safe citrus juice and process for preparation |
| WO2004037827A1 (en) | 2000-10-20 | 2004-05-06 | Bioavailability Systems, Llc | Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP1732891A4 (en) | 2004-03-11 | 2009-05-06 | Sequoia Pharmaceuticals Inc | RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES |
| EP2422781A1 (en) | 2004-05-07 | 2012-02-29 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| US20090281114A1 (en) | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| KR20180084153A (ko) | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型c-kit的方法 |
| ES2750523T3 (es) | 2012-12-18 | 2020-03-26 | Almirall Sa | Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3 |
| US9458124B2 (en) | 2013-02-06 | 2016-10-04 | Wayne State University | Substituted pyran derivatives |
| KR20150130389A (ko) | 2013-03-13 | 2015-11-23 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 |
| WO2015108940A2 (en) | 2014-01-14 | 2015-07-23 | The Trustees Of The University Of Pennsylvania | Tailored combinatorial epigenetic therapies for p53 gain-of-function tumors |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2016025635A2 (en) * | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| EP4643952A3 (en) | 2016-01-26 | 2026-01-14 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1 |
| CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3805215A1 (en) * | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitors of the menin-mll interaction |
| US10899758B2 (en) | 2016-09-16 | 2021-01-26 | Vitae Pharmaceuticals, Llc | Inhibitors of the menin-MLL interaction |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| KR20200101389A (ko) | 2017-12-20 | 2020-08-27 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 엑소-아자 스피로 억제제 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| JP2021519785A (ja) | 2018-03-30 | 2021-08-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 共有結合性メニン阻害剤としてのピペリジン化合物 |
| AU2019337547A1 (en) | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| EP3856173A4 (en) | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS |
| EP3906026A4 (en) | 2018-12-31 | 2022-10-19 | Biomea Fusion, LLC | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION |
| MX2022012471A (es) | 2020-04-07 | 2022-11-30 | Syndax Pharmaceuticals Inc | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. |
| AU2022271791A1 (en) | 2021-05-12 | 2024-01-04 | Board Of Regents, The University Of Texas System | Combinations for treatment of cancer |
| TW202311262A (zh) | 2021-05-14 | 2023-03-16 | 美商錫達斯醫藥股份有限公司 | Menin-mll交互作用之抑制劑 |
| AU2022325861A1 (en) | 2021-08-11 | 2024-02-29 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| CN118234497A (zh) | 2021-12-15 | 2024-06-21 | 丹娜-法伯癌症研究所 | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) |
| TW202525797A (zh) | 2023-08-28 | 2025-07-01 | 美商錫達斯醫藥股份有限公司 | 作為menin-mll交互作用之抑制劑的芳基醚類似物 |
-
2021
- 2021-04-07 MX MX2022012471A patent/MX2022012471A/es unknown
- 2021-04-07 CN CN202510541711.8A patent/CN120393026A/zh active Pending
- 2021-04-07 AU AU2021252552A patent/AU2021252552A1/en active Pending
- 2021-04-07 US US17/917,193 patent/US12564590B2/en active Active
- 2021-04-07 KR KR1020227038376A patent/KR20230007359A/ko active Pending
- 2021-04-07 EP EP21783895.2A patent/EP4132932A4/en active Pending
- 2021-04-07 JP JP2022561040A patent/JP2023522166A/ja active Pending
- 2021-04-07 CA CA3178691A patent/CA3178691A1/en active Pending
- 2021-04-07 CN CN202180040679.5A patent/CN115698013B/zh active Active
- 2021-04-07 IL IL297039A patent/IL297039A/en unknown
- 2021-04-07 CN CN202510541621.9A patent/CN120393025A/zh active Pending
- 2021-04-07 WO PCT/US2021/026141 patent/WO2021207335A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (https=) | ||
| JP2022022264A5 (https=) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| KR101390144B1 (ko) | 염증성 장질환 치료제 | |
| CN102573852A (zh) | 用于治疗ibd的药物组合物 | |
| EP3027183B1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| Seiler et al. | Adverse event management of oral mucositis in patients with breast cancer | |
| JPWO2021207335A5 (https=) | ||
| JP2015517523A5 (https=) | ||
| JP2019533660A5 (https=) | ||
| CN109985237A (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JPWO2020257671A5 (https=) | ||
| US11628163B2 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| JP2022177119A5 (https=) | ||
| WO2024249875A1 (en) | Combinations of estrogen receptor degraders and akt inhibitors | |
| RU2721409C1 (ru) | Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови | |
| ES2554332T3 (es) | Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40 | |
| CN105079012B (zh) | 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| JPWO2022106711A5 (https=) | ||
| JPWO2022218956A5 (https=) | ||
| CN111494371B (zh) | Pyr3的用途 | |
| CN104983728A (zh) | 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| CN104510854A (zh) | 一种治疗妇女痛经的中药组合物及其用途 |